The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
BJD, 2023.
Oras A. Alabas, Kayleigh J. Mason, Zenas Z.N. Yiu, Richard B. Warren, Nick Dand, Jonathan N.W.N. Barker, Catherine H. Smith, Christopher E.M. Grifï¬ths, the BADBIR and BSTOP study group.
Read publication: BJD
Related
Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe pso...
Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-b...
Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective c...
0 Comments